Biopharma Stocks Transformative Innovation for the Future of Health
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
EF Hutton Starts Citius Pharmaceuticals (CTXR) at Buy
July 15, 2024 9:35 AM EDTEF Hutton analyst Jason Kolbert initiates coverage on Citius Pharmaceuticals (NASDAQ: CTXR) with a Buy rating and a price target of $6.00.
The analyst comments "Low-Risk and High-Reward. Citius has two late-stage therapeutics, Mino-Lok (MLT) and LYMPHIR. Both products have demonstrated efficacy and safety and are in the final stages of the approval process.... More
